Parkside Financial Bank & Trust’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22K | Buy |
425
+2
| +0.5% | +$102 | ﹤0.01% | 1270 |
|
|
2025
Q4 | $21K | Buy |
423
+115
| +37% | +$5.59K | ﹤0.01% | 1283 |
|
|
2025
Q3 | $14.7K | Buy |
308
+274
| +806% | +$11K | ﹤0.01% | 1363 |
|
|
2025
Q2 | $1.07K | Buy |
34
+19
| +127% | +$609 | ﹤0.01% | 2241 |
|
|
2025
Q1 | $492 | Buy |
+15
| New | +$532 | ﹤0.01% | 2403 |
|
|
2023
Q4 | – | Sell |
-183
| Closed | -$5.05K | – | 2174 |
|
|
2023
Q3 | $5.05K | Buy |
183
+15
| +9% | +$457 | ﹤0.01% | 1363 |
|
|
2023
Q2 | $5.05K | Hold |
168
| – | – | ﹤0.01% | 1366 |
|
|
2023
Q1 | $6.09K | Hold |
168
| – | – | ﹤0.01% | 1286 |
|
|
2022
Q4 | $5.99K | Hold |
168
| – | – | ﹤0.01% | 1246 |
|
|
2022
Q3 | $6K | Hold |
168
| – | – | ﹤0.01% | 1175 |
|
|
2022
Q2 | $5K | Sell |
168
-4
| -2% | -$115 | ﹤0.01% | 1261 |
|
|
2022
Q1 | $6K | Buy |
172
+4
| +2% | +$123 | ﹤0.01% | 1248 |
|
|
2021
Q4 | $5K | Buy |
168
+4
| +2% | +$121 | ﹤0.01% | 1346 |
|
|
2021
Q3 | $4K | Sell |
164
-16
| -9% | -$429 | ﹤0.01% | 1363 |
|
|
2021
Q2 | $6K | Buy |
180
+16
| +10% | +$491 | ﹤0.01% | 1186 |
|
|
2021
Q1 | $4K | Hold |
164
| – | – | ﹤0.01% | 1307 |
|
|
2020
Q4 | $4K | Buy |
164
+136
| +486% | +$2.93K | ﹤0.01% | 1222 |
|
|
2020
Q3 | $1K | Sell |
28
-16
| -36% | -$363 | ﹤0.01% | 1431 |
|
|
2020
Q2 | $1K | Buy |
44
+22
| +100% | +$486 | ﹤0.01% | 1387 |
|
|
2020
Q1 | $0 | Sell |
22
-55
| -71% | -$1.16K | ﹤0.01% | 1644 |
|
|
2019
Q4 | $2K | Buy |
77
+29
| +60% | +$704 | ﹤0.01% | 1244 |
|
|
2019
Q3 | $1K | Buy |
+48
| New | +$1.42K | ﹤0.01% | 1449 |
|
|
2019
Q2 | – | Sell |
-54
| Closed | -$2K | – | 1666 |
|
|
2019
Q1 | $2K | Buy |
54
+11
| +26% | +$409 | ﹤0.01% | 1208 |
|
|
2018
Q4 | $1K | Buy |
43
+9
| +26% | +$387 | ﹤0.01% | 1321 |
|
|
2018
Q3 | $2K | Hold |
34
| – | – | ﹤0.01% | 1133 |
|
|
2018
Q2 | $2K | Buy |
34
+3
| +10% | +$155 | ﹤0.01% | 1105 |
|
|
2018
Q1 | $1K | Hold |
31
| – | – | ﹤0.01% | 1288 |
|
|
2017
Q4 | $1K | Hold |
31
| – | – | ﹤0.01% | 1226 |
|
|
2017
Q3 | $1K | Hold |
31
| – | – | ﹤0.01% | 1227 |
|
|
2017
Q2 | $1K | Hold |
31
| – | – | ﹤0.01% | 1252 |
|
|
2017
Q1 | $1K | Hold |
31
| – | – | ﹤0.01% | 1213 |
|
|
2016
Q4 | $1K | Buy |
+31
| New | +$693 | ﹤0.01% | 1210 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Parkside Financial Bank & Trust's SUPN Position: Q1 2026 in Review
Parkside Financial Bank & Trust increased its Supernus Pharmaceuticals (SUPN) stake by 0.47% in Q1 2026, buying an estimated $102 and bringing the position to 425 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #1270.
Parkside Financial Bank & Trust first reported a position in SUPN in Q4 2016 and has held it in 32 quarters since. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Parkside Financial Bank & Trust held 425 shares of Supernus Pharmaceuticals worth $22K as of Q1 2026.
- Parkside Financial Bank & Trust bought 2 Supernus Pharmaceuticals shares in Q1 2026, an estimated $102.
- Supernus Pharmaceuticals made up ﹤0.01% of Parkside Financial Bank & Trust's portfolio in Q1 2026, its #1270 holding.
- Parkside Financial Bank & Trust first reported a position in Supernus Pharmaceuticals in Q4 2016 and has held it in 32 quarters since.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Parkside Financial Bank & Trust's 13F filing for Q1 2026, filed 13 May 2026.